November 2017- Volume 13, Issue 11

In this Issue

Q&A

Q&A: Rare oncology--which types qualify?

Q&A: Rare oncology--which types qualify?

Orphan diseases are seeing increased attention in recent years due to the appeal of markets with low competition, but rare oncology types are another beast entirely

Business & Government Policy

Patent Docs: Allergan avoids PTAB review by assigning patents to Mohawk Nation

Patent Docs: Allergan avoids PTAB review by assigning patents to Mohawk Nation

While a creative solution to avoid patent challenges, this is a move that will likely gain at least some attention from Congress to possibly curb similar actions in the future

New cancer answer

New cancer answer

NanOlogy platform takes chemo directly to the tumor

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Making a PACT with NIH

Making a PACT with NIH

Five-year public-private R&D program established as part of Cancer Moonshot

Clinical Trials

Out of the starting gate

Out of the starting gate

A roundup of clinical trial startups and initial breakthroughs

Just a drop away from relief?

Just a drop away from relief?

SciFluor announces positive results of Phase 1/2 study on eye drops for diabetic macular edema

Personalized biologics for rare skin disease

Personalized biologics for rare skin disease

Fibrocell technology treats patients with cells derived from their own tissue

Change of direction for Prothena

Change of direction for Prothena

Disappointing Phase 1b results cause company to halt PRX003 program in psoriasis

VARI scores twice with SU2C Catalyst

VARI scores twice with SU2C Catalyst

Total of 10 grant awards given out for clinical trials on various cancers

Preclinical

‘Granting’ a heart’s desire

‘Granting’ a heart’s desire

NIH award for CMCs is one of University of Louisville’s largest-ever federal grants for medical research

Could dMAb shake up infection and cancer treatment?

Could dMAb shake up infection and cancer treatment?

Inovio’s DNA-based product shows promise combating Ebola and prostate tumors

Nonclinical cardio safety combo

Nonclinical cardio safety combo

ApconiX Alliance and PhysioStim address drug development failure rate

All about ADCs

All about ADCs

Eisai’s antibody-drug conjugate shows target selectivity and antitumor effects

Contract Services

More room for growth

More room for growth

ADC Bio commits $11M for new clinical, commercial drug manufacturing plant

CPhI report highlights unpredictability in CDMO growth

CPhI report highlights unpredictability in CDMO growth

Flow chemistry, oncology, other aspects to grow, but the rate of change remains unclear

Contract tech roundup

Contract tech roundup

Some recent news of technology at contract research organizations

Research & Development

Making a successful HIV vaccine

Making a successful HIV vaccine

Sugar molecules on HIV envelope are likely target, according to TSRI

OSE and Inserm team up on immuno-oncology

OSE and Inserm team up on immuno-oncology

Research to focus on targeting a new suppressive myeloid cell receptor

A pair of NIH awards for JAX

A pair of NIH awards for JAX

The Jackson Laboratory gets $12.8 million in grants to research chronic fatigue and eye disease

‘Broader’ support for tech advancement

‘Broader’ support for tech advancement

New commitment received at Broad will establish Merkin Institute for Transformative Technologies in Healthcare

Discovery

Selective memory

Selective memory

New Alzheimer’s disease candidate selectively targets toxic AβO

Quality is key in ribosome assembly

Quality is key in ribosome assembly

‘Quality control’ step, when skipped, can cause defects that can lead to cancer and other disease

Making the right choice

Making the right choice

Salk researchers says decisions in DNA repair are aided by a microprotein

Diagnostics

A new angle on two cancers

A new angle on two cancers

ANGLE and QIAGEN form collaboration aimed at liquid biopsies for breast and prostate cancer

Diagnostics tag team

Diagnostics tag team

IDG leverages PerkinElmer’s sequencing services to provide whole-genome sequencing to neurology patients

Rosetta offloads PDx for $2.875M

Rosetta offloads PDx for $2.875M

Sale proceeds will be used to support commercial advancement of Reveal assay

Agilent expands usage for cancer diagnostic

Agilent expands usage for cancer diagnostic

Dako PD-L1 IHC 28-8 pharmDx approved for two new indications

Editor's Focus

Blood will tell: Hematology in review

Blood will tell: Hematology in review

Combing through my inbox, it seems news of therapeutics for (and research into) blood-related diseases, from hemophilia to leukemia, has picked up a little recently...so we thought we'd share some of that news with you

Commentary

Out of order: Art and science

Out of order: Art and science

We want to believe that science is rational and predictable but more often than not, this is only true in hindsight, once we finally “understand” what we are looking at, having viewed it from multiple angles and tested it under a variety of conditions. And even then, the seemingly chaotic nature of science surprises us, and not always in a good way.

A life-sciences columnist with a twist: Getting to know Randy

A life-sciences columnist with a twist: Getting to know Randy

Though he's been with us for more than a decade, we thought we'd introduce (or, for many of you, re-introduce) one of our two regular columnists

Special Reports

Special Report on Sequencing: Qualifying statements

Special Report on Sequencing: Qualifying statements

Are expanding applications pushing next-gen sequencing beyond its limits?

Feature

2017 ASCB-EMBO Show Preview: Showing love for cells in Philly

2017 ASCB-EMBO Show Preview: Showing love for cells in Philly

For the first joint outing of ASCB and EMBO in annual meeting form, the ‘City of Brotherly Love’ will play host
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

September 2022

Latest Issue  

• Volume 18 • Issue 9 • September 2022

September 2022

September 2022